Standard

PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. / Batorov, Egor V; Ineshina, Alisa D; Aristova, Tatiana A et al.

In: Oncology research, Vol. 32, No. 10, 06.2024, p. 1575-1587.

Research output: Contribution to journalArticlepeer-review

Harvard

Batorov, EV, Ineshina, AD, Aristova, TA, Denisova, VV, Sizikova, SA, Batorova, DS, Ushakova, GY, Shevela, EY & Chernykh, ER 2024, 'PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells', Oncology research, vol. 32, no. 10, pp. 1575-1587. https://doi.org/10.32604/or.2024.047893

APA

Batorov, E. V., Ineshina, A. D., Aristova, T. A., Denisova, V. V., Sizikova, S. A., Batorova, D. S., Ushakova, G. Y., Shevela, E. Y., & Chernykh, E. R. (2024). PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. Oncology research, 32(10), 1575-1587. https://doi.org/10.32604/or.2024.047893

Vancouver

Batorov EV, Ineshina AD, Aristova TA, Denisova VV, Sizikova SA, Batorova DS et al. PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. Oncology research. 2024 Jun;32(10):1575-1587. doi: 10.32604/or.2024.047893

Author

BibTeX

@article{28c402ccff0b459086de04ef32a07792,
title = "PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells",
abstract = "BACKGROUND: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules.METHODS: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow cytometry in PD-1- and TIM-3-negative and positive T cells before the conditioning and during the first post-transplant month in peripheral blood samples of MM patients.RESULTS: Substantial proportions of PD-1- and TIM-3-positive T lymphocytes expressed common γ-chain cytokine receptors and pSTAT5. Frequencies of cytokine receptor expressing cells were significantly higher within TIM-3+ T cells compared to PD-1+TIM-3- subsets. Considerable proportions of both PD-1-/TIM-3-negative and positive CD8+ T cells express EOMES, while only moderate frequencies of CD4+ PD-1+/TIM-3+ T cells up-regulate this transcription factor. Besides, the surface presence of CD25 and intranuclear expression of EOMES in CD4+ T cells were mutually exclusive regardless of PD-1 and TIM-3 expression. The stimulation with common γ-chain cytokines up-regulates PD-1 and TIM-3 during the proliferation of initially PD-1/TIM-3-negative T cells but fails to expand initially PD-1+ and TIM-3+ T cell subsets in vitro.CONCLUSIONS: Both PD-1 and TIM-3 expressing T cells appear to be able to respond to homeostatic cytokine stimulation. Differences in common γ-chain cytokine receptor expression between PD-1+ and TIM-3+ T cells may reflect functional dissimilarity of these cell subsets. Checkpoint blockade appears to alleviate lymphopenia-induced proliferation of PD-1+ T cells but may raise the possibility of immune-mediated adverse events.",
keywords = "Humans, Multiple Myeloma/immunology, Hepatitis A Virus Cellular Receptor 2/metabolism, Programmed Cell Death 1 Receptor/metabolism, Middle Aged, Male, Female, Aged, Interleukin-7/metabolism, Interleukin-15/pharmacology, Up-Regulation, Adult, Receptors, Cytokine/metabolism, T-Lymphocytes/immunology",
author = "Batorov, {Egor V} and Ineshina, {Alisa D} and Aristova, {Tatiana A} and Denisova, {Vera V} and Sizikova, {Svetlana A} and Batorova, {Daria S} and Ushakova, {Galina Y} and Shevela, {Ekaterina Y} and Chernykh, {Elena R}",
note = "This work is supported by the Russian Science Foundation (Grant No. 20-75-10132). {\textcopyright} 2024 The Authors.",
year = "2024",
month = jun,
doi = "10.32604/or.2024.047893",
language = "English",
volume = "32",
pages = "1575--1587",
journal = "Oncology research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "10",

}

RIS

TY - JOUR

T1 - PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells

AU - Batorov, Egor V

AU - Ineshina, Alisa D

AU - Aristova, Tatiana A

AU - Denisova, Vera V

AU - Sizikova, Svetlana A

AU - Batorova, Daria S

AU - Ushakova, Galina Y

AU - Shevela, Ekaterina Y

AU - Chernykh, Elena R

N1 - This work is supported by the Russian Science Foundation (Grant No. 20-75-10132). © 2024 The Authors.

PY - 2024/6

Y1 - 2024/6

N2 - BACKGROUND: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules.METHODS: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow cytometry in PD-1- and TIM-3-negative and positive T cells before the conditioning and during the first post-transplant month in peripheral blood samples of MM patients.RESULTS: Substantial proportions of PD-1- and TIM-3-positive T lymphocytes expressed common γ-chain cytokine receptors and pSTAT5. Frequencies of cytokine receptor expressing cells were significantly higher within TIM-3+ T cells compared to PD-1+TIM-3- subsets. Considerable proportions of both PD-1-/TIM-3-negative and positive CD8+ T cells express EOMES, while only moderate frequencies of CD4+ PD-1+/TIM-3+ T cells up-regulate this transcription factor. Besides, the surface presence of CD25 and intranuclear expression of EOMES in CD4+ T cells were mutually exclusive regardless of PD-1 and TIM-3 expression. The stimulation with common γ-chain cytokines up-regulates PD-1 and TIM-3 during the proliferation of initially PD-1/TIM-3-negative T cells but fails to expand initially PD-1+ and TIM-3+ T cell subsets in vitro.CONCLUSIONS: Both PD-1 and TIM-3 expressing T cells appear to be able to respond to homeostatic cytokine stimulation. Differences in common γ-chain cytokine receptor expression between PD-1+ and TIM-3+ T cells may reflect functional dissimilarity of these cell subsets. Checkpoint blockade appears to alleviate lymphopenia-induced proliferation of PD-1+ T cells but may raise the possibility of immune-mediated adverse events.

AB - BACKGROUND: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules.METHODS: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow cytometry in PD-1- and TIM-3-negative and positive T cells before the conditioning and during the first post-transplant month in peripheral blood samples of MM patients.RESULTS: Substantial proportions of PD-1- and TIM-3-positive T lymphocytes expressed common γ-chain cytokine receptors and pSTAT5. Frequencies of cytokine receptor expressing cells were significantly higher within TIM-3+ T cells compared to PD-1+TIM-3- subsets. Considerable proportions of both PD-1-/TIM-3-negative and positive CD8+ T cells express EOMES, while only moderate frequencies of CD4+ PD-1+/TIM-3+ T cells up-regulate this transcription factor. Besides, the surface presence of CD25 and intranuclear expression of EOMES in CD4+ T cells were mutually exclusive regardless of PD-1 and TIM-3 expression. The stimulation with common γ-chain cytokines up-regulates PD-1 and TIM-3 during the proliferation of initially PD-1/TIM-3-negative T cells but fails to expand initially PD-1+ and TIM-3+ T cell subsets in vitro.CONCLUSIONS: Both PD-1 and TIM-3 expressing T cells appear to be able to respond to homeostatic cytokine stimulation. Differences in common γ-chain cytokine receptor expression between PD-1+ and TIM-3+ T cells may reflect functional dissimilarity of these cell subsets. Checkpoint blockade appears to alleviate lymphopenia-induced proliferation of PD-1+ T cells but may raise the possibility of immune-mediated adverse events.

KW - Humans

KW - Multiple Myeloma/immunology

KW - Hepatitis A Virus Cellular Receptor 2/metabolism

KW - Programmed Cell Death 1 Receptor/metabolism

KW - Middle Aged

KW - Male

KW - Female

KW - Aged

KW - Interleukin-7/metabolism

KW - Interleukin-15/pharmacology

KW - Up-Regulation

KW - Adult

KW - Receptors, Cytokine/metabolism

KW - T-Lymphocytes/immunology

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85204759554&origin=inward&txGid=86c4cee83ecb17e7372614f8e321dbbe

UR - https://www.mendeley.com/catalogue/abdde6c2-f58f-33d6-b28f-9106ce5ab37a/

U2 - 10.32604/or.2024.047893

DO - 10.32604/or.2024.047893

M3 - Article

C2 - 39308517

VL - 32

SP - 1575

EP - 1587

JO - Oncology research

JF - Oncology research

SN - 0965-0407

IS - 10

ER -

ID: 61161009